|CHAPTER 1:||Risk Factors and Diseases Causing Chronic Kidney Disease|
|Topic 2||Clinical Practice Guidelines|
The National Kidney Foundation, Inc. Kidney Disease Outcomes Quality Initiative (K/DOQI) Work Group for Chronic Kidney Disease (CKD) developed clinical practice guidelines in the year 2000 with an educational grant from Amgen, Inc.
Stages & Classifications
The K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification is a manual developed for healthcare professionals. It provides direction for early identification and appropriate treatment that can result in improved patient outcomes.
Chronic kidney disease is defined as either kidney damage or GFR <60 mL/min/1.73 m2 for >=3 months.
Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.
GFR (Glomerular Filtration Rate) is a formula used to assess kidney function.
Includes 15 recommendations related to the assessment and classification of chronic kidney disease, association of level of kidney function with complications and a stratification of risk for progression and development of cardiovascular disease in CKD.
|1||Kidney damage with normal or high GFR (Glomerular filtration rate)||>=90||Diagnosis and treatment, treatment of comorbid conditions, slowing progression and cardiovascular disease risk reduction|
|2||Kidney damage with mild low GFR||60-89||Estimating progression|
|3||Moderate low GFR||30-59||Evaluating and treating complications|
|4||Severe low GFR||15-29||Preparation for renal replacement therapy (RRT)|
|5||Kidney failure||<15 (or dialysis)||Replacement (if uremia present)|
National Kidney Foundation | 30 East 33rd Street New York, NY 10016 | 1-800-622-9010 | www.kidney.org